SENS is another related company listed on NASDAQ They have developed a product that transmits blood glucose readings to your smart phone...although invasively just like Dexcom.
Oppenheimer Funds invested 8million in the company recently along with Blackrock who invested 37 million. All for a similar device to Dexcom.
That’s a ton of cash to invest in something that already exists. That shows the potential of this technology and how valuable it is and will be.
What this tells me is there is Plenty of room at the inn. Know has a significant leg up with its long list of patents of already issued patents.
Thay just received a “notice of allowance from the US Patent and trademark office” on an important addition to its patent portfolio covering foundational elements of its technology. The CEO said they received the letter from USPO in mid December and typically it takes about 6 weeks to be awarded the patent. You don’t get that notice unless you are going to be awarded the patent. Once they have the patent in hand in combination with all the patents they already have they are golden.
No one can infringe on their method. Which is the only one up to now that has shown to accurately read blood glucose and other molecules non-invasively. Mark Tapsak white paper from early 2019 that inspired him to leave Dexcom and join know.
So let’s review we have:
1. All star board of former FDA dr’s and medical device experts with diabetes experience
2. A working prototype that is close to being miniaturized( and could be done already for all we know),
3. selection of world class Racer for production
4. FDA application around the corner once miniaturization is complete
5. fantastic share structure.
18.44 million o/s currently with only 10.36 in the float
56 million total. Including all warrants, options and restricted shares
6. No convertible debt
7. US and India market access (one of the board members is also a director of one of the largest medical device distributors in India) which btw has the largest diabetic population in the world
8. Recently company was approached by one of the largest and most prestigious research clinics in the country proposing an independent trial of their technology
9. CEO wants to uplist ASAP, even before FDA approval because then the big medical tech funds ( like Oppenheimer, blackrock mentioned above) can start to invest and with that small float the share price should really start to move.
Its Obvious big buying has come into this stock over the last 6 weeks. Just look at the chart.
I like competition, it’s healthy. Especially when you are the pace car. These other companies will be eating our dust for years to come. They don’t have the intellectual property strategy KNWN has.
We are so golden here. $100-$200 stock before we know it IMOP
GLTA
